IECM
WST icon

Intrinsic Edge Capital Management’s West Pharmaceutical WST Stock Holding History

Intrinsic Edge Capital Management’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-15,000
Closed -$6.16M – 230
2022
Q1 		$6.16M Buy
15,000
+10,000
+200% +$3.91M 0.47% 83
2021
Q4 		$2.35M Buy
+5,000
New +$2.15M 0.15% 157
2021
Q1 		– Sell
-7,767
Closed -$2.2M – 273
2020
Q4 		$2.2M Buy
+7,767
New +$2.18M 0.16% 168

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $40.7B AUM 39.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Intrinsic Edge Capital Management's WST Position: Q2 2022 in Review

Intrinsic Edge Capital Management sold out of West Pharmaceutical (WST) in Q2 2022, closing a stake of 15,000 shares — an estimated $6.16M sold.

Intrinsic Edge Capital Management first reported a position in WST in Q4 2020 and held it in 3 quarters. The position peaked at $6.16M in Q1 2022. 655 funds tracked by Wall St. Rank hold WST as of Q2 2022.

  • Intrinsic Edge Capital Management reported no remaining West Pharmaceutical position as of Q2 2022 after selling out during the quarter.
  • Intrinsic Edge Capital Management sold 15,000 West Pharmaceutical shares in Q2 2022, an estimated $6.16M.
  • Intrinsic Edge Capital Management first reported a position in West Pharmaceutical in Q4 2020 and held it in 3 quarters.
  • Intrinsic Edge Capital Management's West Pharmaceutical position peaked at $6.16M in Q1 2022.
  • 655 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2022.

Based on Intrinsic Edge Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.